Objectives <p>We aimed to evaluate the effectiveness of nasal irrigation sprays at treating rhinosinusitis by easing congestion in the nose and other symptoms.</p> Methods <p>A total of 1700 individuals diagnosed with rhinosinusitis were assigned to the following groups: One group used Sinomarin<sup>®</sup> hypertonic nasal spray (<i>n</i> = 600), another used Sinomarin<sup>®</sup> Plus Algae ENT hypertonic nasal spray (<i>n</i> = 600), and a third used an isotonic saline nasal spray (<i>n</i> = 500). Before and after therapy, patients had their symptoms and turbinates examined, overall symptoms scored, and quality of life (QoL) evaluated.</p> Results <p>The findings showed that both groups saw a decrease in symptom scores for anterior discharge, postnasal drip, headache, and obstruction with therapy, as well as an improvement in turbinate color and edema (<i>p</i> &lt; 0.05). Quality of life (QoL) ratings rose, and total symptom scores fell during therapy. The group that used hypertonic nasal spray with algae had considerably fewer overall symptom scores than the other groups (hypertonic nasal spray and saline). The hypertonic nasal spray group reported substantially fewer symptoms than the saline group. For what concerns quality of life, the saline group had significantly worse scores than groups 1 and 2; groups 1 and 2 were similar to one another.</p> Conclusion <p>We found that compared to hypertonic and saline nasal sprays, the algae-containing hypertonic spray reduced total symptom scores more than the other sprays. This indicated that irrigation based on algae-containing hypertonic nasal sprays could be the treatment of choice for the management of symptoms in rhinosinusitis patients.</p> Clinical trial number <p>The study was registered to ClinicalTrials.gov Protocol Registration and Results System (PRS) with a Clinical trial number of E-95961207-202.3.02-2955.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Efficacy of hypertonic nasal spray with algae in rhinosinusitis

  • Zeynel Öztürk,
  • Nuray Bayar Muluk,
  • Rahime Koca,
  • Necdet Özçelіk,
  • Elvin Alaskarov,
  • İbrahim Çukurova,
  • Erdem Atalay Çetіnkaya,
  • Özgür Yörük,
  • Cengiz Bal,
  • Arzu Tatar,
  • Nihat Susaman,
  • Nagehan Dilşad Erdoğmuş Küçükcan,
  • Ayten Güner Atayoğlu,
  • Enes Güngör,
  • Burak Mustafa Taş,
  • Cemal Cingi

摘要

Objectives

We aimed to evaluate the effectiveness of nasal irrigation sprays at treating rhinosinusitis by easing congestion in the nose and other symptoms.

Methods

A total of 1700 individuals diagnosed with rhinosinusitis were assigned to the following groups: One group used Sinomarin® hypertonic nasal spray (n = 600), another used Sinomarin® Plus Algae ENT hypertonic nasal spray (n = 600), and a third used an isotonic saline nasal spray (n = 500). Before and after therapy, patients had their symptoms and turbinates examined, overall symptoms scored, and quality of life (QoL) evaluated.

Results

The findings showed that both groups saw a decrease in symptom scores for anterior discharge, postnasal drip, headache, and obstruction with therapy, as well as an improvement in turbinate color and edema (p < 0.05). Quality of life (QoL) ratings rose, and total symptom scores fell during therapy. The group that used hypertonic nasal spray with algae had considerably fewer overall symptom scores than the other groups (hypertonic nasal spray and saline). The hypertonic nasal spray group reported substantially fewer symptoms than the saline group. For what concerns quality of life, the saline group had significantly worse scores than groups 1 and 2; groups 1 and 2 were similar to one another.

Conclusion

We found that compared to hypertonic and saline nasal sprays, the algae-containing hypertonic spray reduced total symptom scores more than the other sprays. This indicated that irrigation based on algae-containing hypertonic nasal sprays could be the treatment of choice for the management of symptoms in rhinosinusitis patients.

Clinical trial number

The study was registered to ClinicalTrials.gov Protocol Registration and Results System (PRS) with a Clinical trial number of E-95961207-202.3.02-2955.